Pliant Therapeutics

Historical price data

Pliant Therapeutics is a clinical-stage biotech focused on discovering and developing breakthrough therapies for fibrotic diseases, a class of serious conditions with high unmet medical need. The company's scientific foundation is built on targeting tissue-specific integrins to inhibit TGF-β activation, aiming for a superior therapeutic profile compared to broad TGF-β inhibitors. Its lead asset, bexotegrast, has demonstrated promising Phase 2a data in IPF and PSC, positioning the company to potentially address multi-billion dollar markets. Pliant's strategy leverages a proprietary integrin platform to build a pipeline of oral therapies for fibrosis across multiple organs.

Proprietary platform for developing oral, small molecule inhibitors that selectively target integrins (αvβ1, αvβ6) to locally inhibit TGF-β activation in fibrotic tissues, aiming for a superior therapeutic index.

In IPF, Pliant competes with approved drugs pirfenidone and nintedanib, and other novel mechanisms in development. Its key differentiator is an oral, tissue-specific TGF-β inhibition strategy. In PSC, the landscape is more open with no approved therapies, positioning bexotegrast as a potential first-in-class candidate. The Novartis collaboration provides strategic validation and resources.